Organismal homeostasis requires a precise balance between self-renewal and differentiation. Physiologically, the presence of limited numbers of stem cells in different tissues provides a hierarchical organization of cell types in which a few daughter cells retain a regenerative potential while most enter an irreversible process of differentiation that culminates in the generation of specialized cell types that are destined to die 1 . The existence of stem cells has been documented in multiple tissues, including the haematopoietic 2 and central nervous 3 systems, and the intestine 4 , skin 5 , cardiac muscle 6 and lung 7 . Similar to their non-transformed counterparts, tumours contain heterogeneous cell populations at various stages of differentiation, suggesting that they might be sustained by relatively undifferentiated transformed progenitors, known as cancer stem cells (CSCs) 8, 9 . Recently, the stem cell-like attributes of self-renewal and multipotency have been discovered in subsets of memory T lymphocytes. In this Review, we describe evidence supporting the existence and function of T memory stem cells (T SCM ). We further discuss how T helper (T H ) 17 cells and interleukin-17 (IL-17)-producing CD8 + T cells also exhibit stem cell-like behaviours. We highlight how signalling pathways that operate in embryonic stem cells, adult stem cells and CSCs, including WNT-β-catenin, SMAD, signal transducer and activator of transcription 3 (STAT3) and forkhead box O (FOXO) signalling, are active in subsets of T lymphocytes. Finally, we envision how triggering these pathways in tumour-reactive T cells or reprogramming terminally differentiated tumour-infiltrating lymphocytes (TILs) to confer stem cell-like properties might be used to augment immunotherapies against cancer and CSCs, which would be akin to fighting 'fire with fire' .
The heterogeneity of memory T cells
Analogous to other organ systems, mature T cells are comprised of cells that are at various stages of differentiation, which are discernible by the expression of surface molecules, anatomic location and function [10] [11] [12] (FIG. 1) . T cell subset diversity results from antigenic and environmental stimuli received during T cell priming and subsequent recall responses. In a primary immune response, antigenspecific naive T (T N ) cells encounter professional antigen-presenting cells (APCs) that have processed and presented tumour-associated antigens in the context of major histocompatibility complex molecules. Signals from multiple parameters, including the strength of T cell receptor (TCR), the balance of co-stimulatory and inhibitory molecules, and the quality of the inflammatory milieu, are integrated in responding T cells to initiate a programme of proliferation and differentiation, which culminates in the formation of effector T (T EFF ) cells 13 (FIG. 1) . Depending on the strength of signalling received [13] [14] [15] , T cells differentiate into distinct subsets characterized by phenotypic and functional changes that are assessable through the use of polychromatic flow cytometry 16 or, more recently, through mass cytometry 17 . Although the lineage relationship between T cell subsets remains controversial 18 (BOX 1), T cells cluster in populations that can be arranged as a progressive continuum on the basis of phenotypic, functional and transcriptional attributes Tumour-infiltrating lymphocytes (TILs) . The heterogeneous population of T cells found in a tumour bed. These cells are characterized by a diversity of phenotypes, antigen specificities, avidities and functional characteristics. They can be activated and expanded ex vivo and re-infused into a tumour-bearing host to mediate tumour regression.
Mass cytometry
Also known as cytometry by time-of-flight (CyTOF). A platform that couples flow cytometry with mass spectrometry. This technique enables the simultaneous evaluation of at least 45 simultaneous phenotypic and functional parameters on a single cell without the use of fluorescent agents or interference from spectral overlap.
Senescence
A biological process by which cells undergo growth arrest after extensive replication.
Homeostatic proliferation
A process of activation and proliferation of leukocytes in a lymphopaenic environment. T cell homeostatic proliferation is driven by T cell receptor interactions with self-peptide-MHC complexes and responsiveness to homeostatic cytokines such as interleukin-7 (IL-7), IL-15 and possibly IL-21.
Progressive T cell differentiation. T N cells are conventionally defined by the co-expression of the RA isoform of the transmembrane phosphatase CD45, the lymph node homing molecules L-selectin (CD62L) and CCR7, and the co-stimulatory receptors CD27 and CD28 (REF. 20) (FIG. 1) . These phenotypic attributes facilitate T cell entry into secondary lymphoid organs to probe APCs for cognate antigen and to respond to activating signals that give rise to more differentiated memory and effector progeny 21 . T cell activation results in the expression of the RNA-binding protein heterogeneous nuclear ribonucleoprotein L-like (HNRPLL), which regulates the alternative splicing of pre-mRNA encoding CD45 to form CD45RO, the prototypical antigen-experienced T cell marker 22, 23 (FIG. 1) .
Among CD45RO-expressing T cells, two major subsets of memory T lymphocytes can be distinguished on the basis of CD62L and CCR7 expression 24 . Similar to T N cells, CD62L and CCR7 are maintained on central memory T (T CM ) cells, whereas these molecules are lost on more differentiated effector memory T (T EM ) cells (FIG. 1) . Functionally, these phenotypic differences allow antigenspecific T CM and T EM cells to patrol central lymphoid organs and peripheral tissues, respectively 21, 24 . The co-stimulatory receptors CD27 and CD28 are also found on the majority of memory T cells; however, expression can be lost as cells become terminally differentiated by progressively acquiring inhibitory signalling molecules, such as killer cell lectinlike receptor subfamily G, member 1 (KLRG1) 17, 25 and through transition into senescence 17, 26 (FIG. 1) . In contrast to T N cells, memory T cells are capable of rapidly releasing cytokines on restimulation 27 . Although both subsets are capable of producing tumour necrosis factor-α (TNFα), T CM cells more efficiently secrete IL-2, and T EM cells have an increased capacity for interferon-γ (IFNγ) release and cytotoxicity 17, 24 (FIG. 1) . All antigen-experienced T cells upregulate the common IL-2 and IL-15β receptor (IL-2Rβ) -conferring the ability to undergo homeostatic proliferation in response to IL-15 (REFS 28, 29) -and also display high amounts of CD95 (also known as FAS) 30 , a receptor that provides either co-stimulatory or pro-apoptotic signals depending on the efficiency of CD95 signalling complex formation and on which particular intracellular signalling proteins are part of the complex 31 (FIG. 1) .
Recently, CD95 and IL-2Rβ have been found to be expressed in a subset of phenotypically naive-appearing T cells 19 . These cells were observed in viral and tumourreactive T cell populations and, similar to conventional memory T cells, displayed a diluted content of TCR excision circles, possessed the ability to rapidly release cytokines on activation and proliferated in response to IL-15 (REF. 19 ). These cells, which are the least differentiated population of antigen-experienced T cells identified to date, were termed stem cell memory T (T SCM ) cells by virtue of their enhanced capacity to self-renew and their multipotent ability to generate all memory and effector T cell subsets 19 .
A model of T cell differentiation in which cells proceed from T N cells to T SCM , T CM and T EM cells is supported not only by progressive phenotypic and functional changes, but also by findings using wholetranscriptome analyses. These data revealed that two-thirds of differentially expressed genes are progressively upregulated or downregulated in the order T N cells to T SCM cells to T CM cells and finally to T EM cells 19 . The expression of genes that encode transcription factors that are associated with T N cells, including the WNT-β-catenin signalling transducers T cell factor 7 (TCF7) and lymphoid enhancer-binding factor 1 (LEF1), multiple members of the Kruppel-like factor (KLF) family, Forkhead box P1 (FOXP1) and the inhibitor of DNA-binding 3 (ID3), is progressively lost as cells transition from T SCM to T CM and T EM subsets 19 ( FIG. 1) . Conversely, ID2, eomesodermin (EOMES), T-box 21 (TBX21; also known as T-BET), PR domaincontaining 1 with ZNF domain (PRDM1; also known as BLIMP-1) and zinc finger E-box binding homeobox 2 (ZEB2), which each encodes key transcriptional regulators of effector differentiation are acquired in the order T SCM cells to T CM cells to T EM cells 19 (FIG. 1) .
These findings suggest that CD8 + T cell differentiation proceeds as a function of the graded expression of key naive or effector-associated transcription factors rather than being determined by the selective expression of subset-specific regulators.
Recently, small non-protein-coding RNAs with regulatory properties termed microRNAs (miRNAs) have been found to tune key aspects of both stem cell 32 and mature T cell functions [33] [34] [35] . Although a comprehensive profiling of miRNA expression across all naive, memory and effector T cell subsets has yet to be carried out, existing data demonstrate that subsets of miRNAs are reciprocally expressed in T N cells, T EM and T EFF cells 36, 37 (FIG. 1) . Although little is known about the function of specific miRNAs in mature CD8 + T cells, miR-29, which is expressed in T N cells, can limit effector functions through its ability to inhibit Eomes, Tbx21 and Ifng 33, 34 , whereas miR-155, which is upregulated in T EM cells, is linked to the development of inflammatory T H 1 and T H 17 subsets 35 and T cell-mediated graft versus host disease 38 . These findings offer the possibility that graded changes in miRNA expression might influence T cell differentiation that is analogous to what was observed using gene expression profiling. Thus, although multiple models have been proposed to 41 . Like stem cells, memory lymphocytes can self-renew throughout the lifetime of the host 39, 40 and they exhibit multipotency, as shown by their ability to differentiate into both effector and memory populations 39, 40 . To confer diverse fates among daughter cells, stem cells undergo asymmetric cell division 42 . This process, which is also active in B and T lymphocytes during priming 43, 44 , has recently been proposed as a mechanism for the simultaneous generation of effector and memory daughter cells by memory T cells on secondary encounter with a pathogen 45 . Commitment to an effector fate might result from the asymmetric segregation of IL-2Rα and T-BET, two crucial drivers of effector differentiation 46, 47 , in daughter cells 45 . Finally, unlike most somatic cells, both stem cells and memory lymphocytes can activate telomerase to maintain telomere length and replicative potential 48, 49 . Among memory T cells, T CM cells were previously thought to represent the stem cell-like memory subset because of their enhanced capacity to undergo selfrenewal and asymmetric division, as well as their higher replicative potential relative to T EM cells, which are committed progenitor cells that are prone to terminal differentiation 39 . The identification of T SCM cells repositioned T CM cells as a more committed cell population in the hierarchy of T cell potency and differentiation 19, 50 . The existence of T SCM cells has been documented in mice, humans and non-human primates 19, [51] [52] [53] (TABLE 1) . This cell population 
Asymmetric cell division
A conserved mechanism by which a cell divides into daughter cells of unequal size and cytoplasmic content, thus conferring differential developmental fates to progeny cells.
Telomere
The segment at the end of chromosomal arms consisting of a series of repeated DNA sequences (TTAGGG in all vertebrates) that regulates chromosomal replication at each cell division.
Stem cell niche
A specialized microenvironment containing stem cells that supports their maintenance and regulates their function.
is identifiable in multiple species by the expression of a core set of markers, including CD62L, CCR7, IL2Rβ, BCL-2 and the chemokine (C-X-C motif) receptor 3 (CXCR3) 19, 51, 52 . Multiple lines of evidence indicate that T SCM cells possess stem cell-like attributes to a greater extent than any other memory lymphocyte population. Experiments using carboxyfluorescein succinimidyl ester to track cell division have demonstrated that T SCM cells regenerate themselves while giving rise to more differentiated progeny in both mice and humans 19, 52 . Although both T CM and T EM cells can also undergo self-renewal, the capacity to form diverse progeny is progressively restricted, so that only T SCM cells are capable of generating all three memory subsets and T EFF cells; T CM cells can give rise to T CM , T EM and T EFF cells; and T EM cells can only produce themselves and T EFF cells 19 . Thus, these data establish T SCM cells at the apex of lineage potential among memory T cells
. Consistent with this hierarchy, the proliferative and survival responses of memory T cell subsets to antigenic or homeostatic stimuli progressively decrease from T SCM cells to T CM cells and T EM cells 19, 52 , possibly as a function of a stepwise loss of telomere length 24, 54 . Moreover, the refractoriness of T SCM cells to undergo attrition in the absence of cognate antigen relative to other memory T cell subsets ensures a long-term reservoir of multipotent antigen-specific memory cells 53 . Perhaps the most compelling evidence for T SCM cell stemness comes from experiments in mice showing the ability of these cells to reconstitute the full diversity of the memory T cell compartment on serial transplantation 52 . Altogether, these findings support the conclusion that stem cell-like cells exist as part of the adaptive immune system in the form of memory T lymphocytes contained in a phenotypically naive-appearing T cell compartment.
Self-renewal pathways in stem cells and T cells
Stem cells are continuously maintained in a poised state between self-renewal and differentiation 55 . What ultimately guides stem cells between these alternative fates are instructive and permissive signals that are provided by growth factors in the stem cell niche 56 . Studies of embryonic stem cells (ESCs), tissue-specific adult stem cells and CSCs have revealed that a common set of cellsurface receptors and intracellular signal transduction pathways contribute to the regulation of this balance 8, 57 . Here, using ESCs as a prototypical model, we highlight how many of these same pathways are active in mature T cell subsets, promoting either self-renewal or T cell differentiation.
STAT3 and SMAD signalling. It has long been recognized that ESCs can be maintained in an undifferentiated state in the presence of leukaemia inhibitory factor (LIF) or related cytokines acting through receptor complexes containing the GP130 signal transducer 58 . The ability of LIF to promote self-renewal depends on the downstream activation of Janus kinase (JAK) and STAT3 (REFS 59, 60) (FIG. 2) . Recently, LIF-STAT3 signalling has been shown to induce KLF4 and KLF5 to reinforce the pluripotency network and to promote ESC self-renewal 61 . In addition to STAT3 activation, signalling through the LIF receptor-GP130 complex can also recruit the adaptor molecule protein tyrosine phosphatase, non-receptor type 11 (also known as SHP2) to activate the MAPK pathway, which delivers pro-differentiation rather than self-renewal cues 62, 63 (FIG . 2) . However, bone morphogenetic proteins (BMPs) can limit MAPK-driven differentiation and enhance ESC self-renewal by inducing the expression of both dual specificity phosphatase 9 (DUSP9) 64 , a MAPK phosphatase and ID proteins in a SMAD-dependent manner 65 (FIG. 2) .
ID proteins block ESC differentiation by antagonizing the transcriptional activity of E proteins as oversupply of transcription factor 3 (also known as E2A) abrogates the ability of ID proteins to sustain ESC maintenance 65 . Recently, Yes-associated protein (YAP), a transcriptional co-activator that is negatively regulated by the AKT and Hippo pathways, has been found to promote ESC selfrenewal by enhancing ID protein expression in response to BMP-SMAD signalling 66 and by inducing numerous pluripotent genes in response to LIF through its binding to the transcription factor TEA domain (TEAD) 67, 68 . These findings indicate that activation of the BMP-SMAD pathway is necessary to direct the response to LIF signalling from differentiation towards self-renewal, and that YAP is capable of potentiating both pathways.
Mature T lymphocytes can also receive environmental signals that trigger STAT3 activity. IL-21 has the unique ability among common γ-chain (γ C ) cytokines to sustain STAT3 activation 69 (FIG. 2) . IL-21 has been shown to suppress the differentiation of CD8 + T cells into T EFF cells, maintaining a T SCM -like state that is associated with high proliferative potential and long-term T cell survival 70 . Experiments in IL-21 or IL-21 receptor-deficient mice revealed that CD8 + T cells undergo greater exhaustion and fail to control viral replication compared with wild-type hosts 71, 72 . CD8
+ T cells were impaired in IL-2
Box 1 | Models of effector and memory T cell lineage relationships
There has been a long-standing controversy regarding how memory T cells form, and about their relationship with effector T cells (T EFF ). The precise understanding of this interrelationship is crucially important for developing immune strategies to enhance T cell responses against cancer. Thus far, three main models of memory formation have been proposed 18 .
• The linear differentiation model 187 : in this model, the priming of naive T cells results in the generation of T EFF cells that are destined either to die or to enter into the effector memory T (T EM ) cell pool. With time, T EM cells can give rise to long-lived central memory T (T CM ) cells. Evidence in support of this model is derived from the observation that T CM cells become the predominant persisting memory T cell subset following the transfer of a population highly enriched for T EM cells.
• The bifuractive differentiation model 43, 188 : this model proposes that a primed naive T cell can give rise to two daughter cells with alternative differentiation fates through asymmetric division. Evidence in support of this model is the finding that there is an unequal partitioning of key molecules and transcription factors that regulate effector differentiation at the first cell division following naive T cell priming.
• The progressive differentiation model (also known as the decreasing potential of memory development or the self-renewing effector model) 19 : this model proposes that, depending on the strength and quality of stimulatory signals received, naive T cells are driven towards progressive stages of differentiation in the order T memory stem cell (T SCM ) to T CM cell and to T EM cell, as cells receive progressively greater signal strengths. This model culminates in the generation of short lived T EFF cells, which are terminally differentiated. Evidence in support of this model include ex vivo phenotypic analyses of virus-specific T cells 189 , measurement of telomere length 24, 54 , gene-expression profiling 19, 190, 191 and in vitro differentiation studies 19, 54 . production, a cytokine that is released by less differentiated T cell subsets 73 , and the depletion of the STAT3 signalling cytokine IL-10 in IL-21-deficient hosts promoted further accumulation of senescent KLRG1 + T cells 74 . IL-6 receptor-α (IL-6Rα) and the signal transducing chain GP130 are highly expressed in T N and T SCM cells, and they are progressively lost with T cell activation and differentiation, suggesting that IL-6-mediated activation of STAT3 might be implicated in the maintenance of less differentiated, multipotent T cells 19, 75, 76 . This hypothesis is supported by the finding that IL-6Rα + CD8 + T cells that were isolated at the peak of a primary immune response had increased long-term survival compared with IL-6Rα − T cells 77 . IL-6Rα was not merely a marker of memory-forming potential, as activated T cells failed to generate physiological numbers of memory cells following adoptive transfer into IL-6-deficient mice 77 . Taken together, these findings indicate that STAT3 signalling cytokines, including IL-6, IL-10 and IL-21, inhibit effector T cell differentiation and exhaustion while promoting long-term memory.
The role of STAT3 signalling in the formation and maintenance of CD8 + memory T cells has recently been investigated 74 . STAT3-deleted T cells have a shortened lifespan, fail to form less differentiated T CM cells and have reduced expression of the memory-associated transcription factor BCL-6 compared with wild-type cells 74 . Furthermore, STAT3-deficient CD8 + T cells are less able to self-renewal and are impaired in their protective capacity against a secondary infection 74 . These findings extend beyond mice, as human patients with autosomaldominant hyper-IgE syndrome have a cell-intrinsic defect in T CM formation and an impaired capacity to control intracellular viral infections 78 . As observed in ESCs, STAT3 might limit cell differentiation by inducing KLF transcription factors that promote cell quiescence and the expression of lymphoid-homing molecules in mature T lymphocytes 79, 80 .
Analogous to ESC biology, ID proteins have now emerged as key regulators of CD8 + T cell memory formation. CD8 + T cells lacking Id3 failed to form physio logical numbers of memory cells and enforced expression was sufficient to rescue long-term survival of terminally differentiated KLRG1 + T cells 81, 82 . As observed in ESCs, ID3 was found to mediate its effect by limiting the activity of E proteins. Indeed, deletion of E2A in CD8 + T cells augmented memory T cell formation in response to a viral infection, recapitulating the phenotype caused by enforced expression of ID3 (REFS 81, 83) .
Similar to ESC biology, YAP has recently been shown to prevent the acquisition of senescence in CD8 + T cells responding to viral infection 84 . Activation of CD8 + T cells in the presence of the pro-differentiating cytokine IL-2 caused the induction of key components of the Hippo pathways, resulting in the degradation of YAP and in the gain of differentiation-associated molecules. Conversely, ectopic expression of a YAP isoform not susceptible to Hippo-mediated negative regulation suppressed the induction of the master of regulator of terminal differentiation BLIMP1, and favoured the maintenance of IL-7Rα + and KLRG1 − memory precursors. It remains to be determined whether YAP may also augment the expression of transcriptional regulators of stemness, including STAT3 and ID family members, in T cells as it does in ESCs.
Interestingly, STAT3 and SMAD signalling can be triggered by several type 17-polarizing cytokines, including IL-6, IL-21 and transforming growth factor-β (TGFβ), suggesting that these pathways might be activated in T H 17 cells to regulate stem cell-like behaviour [85] [86] [87] 
. In summary, STAT3 signalling and ID proteins are active in mature T lymphocytes and can promote self-renewal and long-term survival.
WNT-β-catenin signalling pathway. Numerous studies have shown that activation of WNT-β-catenin signalling (FIG. 2) is causally associated with self-renewal 19 CMV, cytomegalovirus; CXCR3, chemokine (C-X-C motif) receptor 3; IL, interleukin; MART1, melanoma antigen recognized by T-cells 1. in ESCs [88] [89] [90] [91] [92] [93] [94] . The activity of this pathway is centred on β-catenin, which in the absence of WNT signalling is targeted for proteasome-dependent degradation by a destruction complex consisting of adenomatous polyposis coli, axin and the serine/threonine kinases casein kinase 1 and glycogen synthase kinase 3β (GSK3β) 95 . On WNT ligation to the Frizzled receptor and low-density lipoprotein co-receptors, a signalling cascade is initiated that results in the disruption of the destruction complex, leading to the accumulation and nuclear translocation of β-catenin 95 (FIG. 2) . Within the nucleus, β-catenin can interact with various DNA-binding partners, notably members of the TCF/LEF family, causing chromatin remodelling and modulation of transcription 95 (FIG. 2) .
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Analogous to ESCs, WNT reporter systems have shown that the WNT-β-catenin pathway is functionally active in mature T lymphocytes 96 . The WNT signalling transducers TCF7 and LEF1 are highly expressed in T N and T SCM CD8 + T cells and are lost with reiterative stimulations and progressive differentiation, which suggests a possible role in maintaining T cells in a less differentiated state 19, 52, 75, 97 . Additionally, Tcf7 and β-catenin are abundantly expressed in T H 17 cells
and in IL-17-producing CD8 + T cells 85, 87 . Although the role of WNT-β-catenin signalling in IL-17-producing cells has yet to be defined, emerging evidence indicates that this pathway is critically important for the formation and long-term maintenance of memory CD8 + T cells 98, 99 . Similar to stem cell biology, WNT3A or inhibitors of GSK3β have been shown to inhibit the differentiation of T N cells into T EFF cells while promoting the generation of self-renewing T SCM and T CM cells 52, 100, 101 . Consistent with these findings, enforced expression of a stabilized form of β-catenin inhibited T cell proliferation and the acquisition of effector functions 102 . Moreover, overexpression of TCF1 and stabilized β-catenin reduced the expansion of CD8 + T cells during the effector phase of the immune response and enhanced the generation of memory T cells in several infection models 103 . Conversely, deletion of TCF1 enhanced effector differentiation, as shown by increased numbers of T cells expressing granzyme B and KLRG1 at the peak of the immune response, preventing + T cell exists that is capable of forming all T cell subsets within its respective lineage. As a cell moves down the hill, its potential to differentiate into other subsets becomes progressively restricted, culminating in a terminally differentiated cell that is destined to die. Cellular differentiation in the Waddington model generally proceeds unidirectionally from the least to the most differentiated cell. However, there is evidence to suggest that cells can dedifferentiate, under some circumstances, and re-occupy a vacant niche, such as that seen in the regeneration of diverse phenotypes like the reacquisition of stem cell antigen 1 in pro-erythrocytes 55 or the re-emergence of CD62L + cells from effector memory T cells 140, 187, 193 , although these processes are highly inefficient under physiological conditions. the establishment of long-term T cell memory 104, 105 . Tcf1-deficient memory T cells were depleted of T CM cells and were severely impaired in their ability to respond to pathogen rechallenge 104, 105 . Defective T cell memory responses could be rescued by the p45 isoform of TCF1 but not by the p33 isoform, which lacks the catenin-binding domain, indicating that TCF1 activity was dependent on its ability to bind to β-catenin 104 .
Recently, the finding that WNT-β-catenin signalling regulates CD8 + T cell memory has been called into question. GSK3β inhibitors were found to arrest effector differentiation even in T cells in which β-catenin was conditionally knocked out 106 . Additionally, memory formation and function were not impaired in mice with a T cell-specific deletion of β-catenin relative to wildtype controls 107 . Confounding the interpretation of these Figure 2 | Signalling pathways regulating self-renewal and differentiation shared between stem cells and T lymphocytes. Self-renewal and differentiation are tightly balanced by opposing signals received from cell surface receptors. Self-renewal is promoted by WNT ligand binding to Frizzled-low-density lipoprotein receptor related protein 5 (LRP5) or LRP6 complexes or by ligand engagement of receptor complexes signalling through signal transducer and activator of transcription 3 (STAT3), including receptors containing the GP130 subunit or the interleukin-21 (IL-21) receptor. Activation of these signalling pathways leads to the transcription of target genes that favour self-renewal and that withhold differentiation, including STAT3 and Kruppel-like factor (KLF) family members and inhibitor of DNA binding (ID) proteins. Conversely, pro-mitotic cytokines such as IL-2 and growth factors can drive cellular differentiation by triggering the PI3K -AKT-mTOR pathway, as well as the RAS-RAF-MAPK pathway. The pro-differentiating influence of the RAS-RAF-MAPK pathway can be counteracted by SMAD signalling that is induced by transforming growth factor-β (TGFβ) or bone morphogenetic protein (BMP) family members through the induction of dual specificity phosphatase 9 (DUSP9) and the E protein regulators, ID molecules. Finally, activation of the Hippo pathways through a poorly characterized ligand-receptor interaction causes inactivation of Yes-associated protein (YAP), resulting in enhanced cellular differentiation. Between these self-renewal and pro-differentiation pathways exists a significant amount of crosstalk such that the net influence of each pathway is finely balanced and tuned. The dashed arrows indicate translocation into the nucleus. APC, adenomatous polyposis coli; CK1α, casein kinase 1, alpha 1; eIF4E, eukaryotic translation initiation factor 4E; FOXO, forkhead box O; GSK3β, glycogen synthase 3β; JAK, janus kinase; LATS, large tumour suppressor; LIF, leukaemia inhibitory factor; MOB, MOB kinase activator 1; MST, mammalian sterile-20-like kinases; p70S6K, p70 ribosomal protein S6 kinase 1; SAV1, salvador homologue 1; SHP2, SH2 domain-containing protein tyrosine phosphatase-2; TCF, T cell factor; TEAD, TEA domain family member; TSC, tuberous sclerosis.
findings is the observation that WNT reporter activity is not extinguished by conditional deletion of β-catenin, suggesting that additional transducers of WNT signals compensate for β-catenin deficiency 96 . Moreover, it should be noted that a 52 kDa truncated β-catenin protein containing at least three of the seven armadillo repeats that mediate interaction with TCF is generated after cremediated deletion of exon 2 to exon 6 of the Ctnnb1 locus, and this fragment might retain some functionality 96, 108, 109 . Furthermore, γ-catenin, an armadillo repeat-containing homologue of β-catenin that is also regulated by the destruction complex, can promote TCF/LEF transcriptional activity in β-catenin-deficient cells 110 . In contrast to that observed in CD8 + T cells that are conditionally deficient in β-catenin 107 , T cells lacking both β-catenin and γ-catenin were found to be severely compromised in mediating recall responses 104 . In summary, extensive evidence indicates that WNT-β-catenin signalling inhibits cell differentiation while promoting stemness not only in stem cells but also in mature T lymphocytes.
PI3K-AKT-mTOR signalling pathway. mTOR is a nutrient-sensitive kinase that regulates cell growth and metabolism. mTOR functions as a central metabolic node that integrates signals from multiple sources, including cytokines and growth factors via the PI3K-AKT pathway, as well as WNT ligands through GSK3β (FIG. 2) . Although mTOR activity is essential for the survival and maintenance of pluripotency in ESCs 111 , increased signalling through this pathway can also drive ESC differentiation by promoting protein translation via p70 ribosomal protein S6 kinase 1 (p70S6K) 112, 113 . Indeed, enhanced p70S6K activity by knockdown of tuberous sclerosis 2 (TSC2), a negative regulator of mTOR, or enforced expression of a constitutively active form of p70S6K impaired ESC self-renewal, indicating that protein synthesis is a major driver of ESC differentiation 100 . mTOR has now emerged as a crucial regulator of CD8 + T cell memory. Similar to ESCs, the activity of mTOR is tightly regulated in T cells to dictate cell fate decisions. For example, high doses of the mTOR inhibitor rapamycin can abrogate CD8 + T cell immune responses, whereas unrestrained mTOR activity by deletion of Tsc1 abrogates T N cell quiescence, resulting in T cell effector differentiation and apoptotic cell death 114, 115 . Notably, modulation of mTOR activity with low doses of rapamycin has a profound quantitative and qualitative effect on memory responses, resulting in increased numbers of memory T cells, as well as the preferential formation of T CM cells 114, 116 . Retroviral transduction of short hairpin RNAs targeting p70S6K and eukaryotic translation initiation factor 4E (eIF4E) recapitulated the immunostimulatory activity of rapamycin in memory formation 114 , demonstrating that restraint of mTOR-mediated protein translation can enhance self-renewal and can limit differentiation not only in ESCs but also in CD8 + T cells. AKT, a serine/threonine-specific protein kinase the activity of which augments mTOR signalling, has also been found to control CD8 + T cell effector and memory differentiation [117] [118] [119] . Sustained AKT function by expression of a constitutively active form of AKT induced terminal differentiation and loss of CD8 + memory T cells 117, 119 , whereas pharmacological blockade of AKT increased CD8 + memory T cell numbers by rescuing the survival of KLRG1 + short-lived T EFF cells 117 . AKT activity enhanced effector differentiation by promoting mTOR signalling and inhibiting FOXO1 activity through cytosolic sequestration, resulting in augmented T-BET expression and IFNγ production, as well as repression of pro-memory factors, including KLF2, IL-7Rα and BCL-6 (REFS 117, 118, (120) (121) (122) (123) (124) . Recently, FOXO1 has been shown to be essential for the maintenance of ESC pluripotency 125 , again emphasizing the conserved nature of many of the signalling pathways that balance self-renewal and differentiation in both ESCs and mature T cells.
Conferring stemness to T cells for therapy
Immunotherapies based on the adoptive transfer of naturally occurring or genetically redirected tumour-reactive T cells represent the best evidence of the therapeutic power of T cells. Such approachs can mediate durable complete responses in a minority of patients with advanced haematological [126] [127] [128] [129] and solid cancers 130, 131 . Why certain patients respond to T cell therapy while others do not remains poorly understood. Undoubtedly, multiple factors can influence the effect of T cell-based therapies, including tumour-and host-associated factors 132 ; however, the ability of T cells to engraft and persist long-term seems to be a prerequisite for success 128, 130, 133, 134 . T cell persistence has been highly correlated with tumour responses across multiple clinical trials and has been linked to intrinsic T cell properties that are reflective of their differentiation state and replicative history (FIG. 1) .
Box 3 | Stem cell-like qualities in CD4
+ T cell subsets CD4 + T cells have crucial roles in coordinating immune responses to infectious diseases and cancer. Despite a wealth of knowledge relevant to CD4 + T cell biology and our increasing understanding and identification of new subsets, relatively little is known about memory CD4 + T cells and the ability of different CD4 + T helper (T H ) cell subsets to persist long term 194 . The functional diversity and, in particular, the developmental plasticity of the T H subsets has posed unique challenges in defining memory in this lineage and has sometimes led investigators to incorrect conclusions. For example, T H cells releasing interleukin-17 (IL-17) (T H 17) have been purported as short-lived effector cells, as these cells display some phenotypic traits that are characteristic of terminally differentiated CD8 + T cells (that is, a lack of expression of CD62L and CD27), and IL-17A production by antigen-specific cells is extinguished over time during an infection 195 . However, this interpretation is at odds with recent evidence indicating that congenically marked highly purified T H 17 cells exhibit not only superior recall and persistence relative to interferon-γ (IFNγ)-secreting T H 1 cells, but also mediate enhanced auto-immunity and antitumour immunity 85 . Moreover, T H 17 cells were found to exhibit the stem cell-like attributes of multipotency (these cells could give rise to both IL-17-and IFNγ-secreting progeny), activation of stem cell-associated molecular pathways (these cells highly expressed β-catenin and Tcf7) and a shared gene expression signature with early memory CD8 + T cells 85 . 
. Nature Reviews | Cancer For example, longer telomere lengths 130, 135 , a short duration of ex vivo culture and a rapid expansion rate of T cells 136, 137 are each significantly associated with tumour regression in patients. Additionally, the frequency of T CM cells in the infusion product 138 and the expression of the co-stimulatory molecules CD28 and CD27 have been correlated with responses 130, 135, 139 . Altogether, these data suggest that the transfer of less differentiated T cells conveys superior antitumour efficacy relative to terminally differentiated effector cells. Experiments in mice transferring defined T cell populations at all stages of differentiation have formally proved that infusion of less differentiated T cells results in greater expansion, persistence 140, 141 and tumour destruction 19, 52, 70, 120, [142] [143] [144] [145] [146] [147] . Paralleling their engraftment and proliferative potentials, the ability of memory T cells to mediate tumour regression progressively decreases from T SCM cells to T CM cells and T EM cells 19, 52, 144, 147 
. Notably, the robust proliferative potential, long-term survival capacity and the ability to give rise to all memory and effector T cell subsets allows T SCM cells to mediate highly effective tumour regression when limited numbers of cells are transferred, a condition in which other memory T cell subsets have little or no impact 19, 52 . Although tumour eradication is likely to involve multiple components of the innate and adaptive immune systems, maintaining a sustained immunological attack against tumour masses by transferring cells with stem cell-like properties might represent the most efficient approach for directly and indirectly destroying every cancer cell, including CSCs (FIG. 3) . Thus, finding strategies that generate and expand T SCM -like cells is pivotal to the development of the next generation of highly effective T cell-based immunotherapies.
Arresting T cell differentiation. Current methods used to produce T cells for adoptive immunotherapy often rely on variations of a strategy developed more than 20 years ago 148, 149 , before the implication of T cell differentiation on in vivo tumour efficacy was fully appreciated 150 . This approach is dependent on potent activating stimuli, including monoclonal antibodies to CD3, high concentrations of IL-2 and allogeneic feeder cells that allow for the generation of large numbers of tumour-reactive T cells but that inexorably drive T cells towards terminal differentiation and senescence. To limit the detrimental influence of ex vivo expansion on T cell differentiation, new methodologies have been explored, including the use of common γ C cytokines other than IL-2, and small molecules that target key metabolic and developmental pathways 151 (FIG. 4a) .
IL-15 can sustain T cell proliferation without the robust pro-differentiating activity that characterizes IL-2. Although IL-2 promotes T cell differentiation into T EFF and T EM -like cells, priming of T cells in the 70, [155] [156] [157] . IL-21 profoundly inhibits T cell differentiation, allowing for the generation of T SCM -like T cells. In mouse T cells, the use of IL-21, in contrast to IL-2, caused a dose-dependent blockade of the acquisition of the antigen-experience marker CD44 and lytic capacity while preserving the expression of Tcf7, Lef1 and CD62L and while maintaining the ability to secrete IL-2 (REF. 70 ). Similarly, the expansion of human tumour-reactive CD45RA + T cells in the presence of IL-21 prevented the loss of CD45RA, CD62L, CD28, CD27 and IL-7Rα and also retained the ability of the cell to release IL-2 (REFS 156, 157) . Most importantly, T cells primed and expanded in the presence of IL-21 exhibit enhanced antitumour activity compared with cells grown in other γ C cytokines 70 . Emerging evidence indicates that the commitment of a cell between effector or memory fates is regulated by evolutionarily conserved metabolic and developmental pathways that integrate multiple signal inputs from cell surface receptors, including TCR, cytokine, co-stimulatory and growth factor receptors 98, 151, [158] [159] [160] .
Rational modulation of these pathways by small molecules provides an attractive means to alter T cell differentiation and to enhance the fitness of T cells for therapeutic use (FIG. 4a) . As many of these molecules have already been approved for other purposes in patients, the use of these drugs to enhance T cell-based therapies can be rapidly incorporated into new clinical trials. For example, the mTOR inhibitor rapamycin, a drug that is currently used to facilitate solid organ and HSC transplantation 160 , not only enhances the formation of CD8 + memory T cells but also augments their antitumour functions 120 . Similarly, metformin, an AMPK agonist used to treat type 2 diabetes, improves T cell survival, recall responses and in vivo antitumour treatment 116 . Finally, inhibitors of GSK3β that are under clinical evaluation for Alzheimer's disease and other neurodegenerative diseases 161 can be repurposed to potentiate the WNT-β-catenin signalling pathway in T cells to generate self-renewing multipotent T SCMlike cells 19, 52 . Although these reagents are effective at withholding T cell differentiation and potentiating in vivo antitumour functions, they also inhibit T cell proliferation. For this reason, the identification of molecules that uncouple the processes of cell expansion and differentiation is desirable. Recently, pharmacological inhibition of the AKT isoforms AKT1 and AKT2 has been shown to inhibit the acquisition of effector molecules and function while preserving a T CM -like phenotype and migratory capacity without a detrimental effect on cell yield 118 . Thus, inhibitors of AKT might allow for the generation of large numbers of minimally differentiated tumour-reactive T cells for therapeutic purposes.
Reprogramming terminally differentiated T cells.
Chronic antigen stimulation in tumour-bearing hosts can drive tumour-specific T cells towards a state of terminal differentiation and exhaustion [162] [163] [164] . Although TILs can be reactivated and expanded in vitro in the presence of immunostimulatory cytokines, these cells, although sometimes effective, are currently incapable of mediating durable complete responses in most patients 130 . The successful derivation of pluripotent stem cells from mature fibroblasts by the ectopic co-expression of crucial ESC transcription factors 165, 166 or miRNAs 167 has powerfully demonstrated how cell fates can be altered by the manipulation of a few key transcriptional regulators, paving the way for the possibility of reprogramming terminally differentiated TILs into highly effective, stem cell-like tumour-reactive T cells (FIG. 4b,c) .
Since Yamanaka's breakthrough study, numerous groups have shown that induced pluripotent stem (iPS) cells can be produced from different somatic cells, including T lymphocytes by enforced expression of the OCT4, SOX2, KLF4 and MYC transcription factors [168] [169] [170] [171] . Importantly, T cell-derived iPS cells maintain the rearranged variable (V), diversity (D) and joining regions (J) of the TCR chains, indicating that iPS cells generated from TILs could retain their antitumour reactivity. Recent insights into the nature of instructive signalling 
Suicide genes
Genes capable of selectively eliminating the cells into which they have been transduced following the administration of a drug. required for T cell development during thymopoiesis has led to the development of ex vivo methods that support the generation of T cells from ESC 172 , HSC [173] [174] [175] and iPS cells 176 providing the tools for re-differentiating TIL-derived iPS cells. Although conceptually attractive and theoretically feasible, this two-step reprogramming approach (FIG. 4b) is currently inefficient both in terms of the frequency of cells successfully reprogrammed and the duration necessary to achieve full reprogramming.
To overcome these limitations, a single approach to directly reprogramme terminally differentiated TILs into more naive, stem cell-like T cells might be possible. A number of reports have shown that direct reprogramming can be used to differentiate various mature cell types into alternative differentiated tissues such as neurons 177, 178 , cardiomyocytes 179 , blood progenitors 180 and hepatocytes 181 by enforced expression of tissue-specific transcription factors. Adapting this approach, ectopic expression of key T N and T SCM -associated transcription factors or miRNAs might result in the intra-lineage reprogramming of terminally differentiated T EFF cells into less differentiated T cell subsets (FIG. 4c) 
Concluding remarks
It is now clear that subsets of mature T cells exist that are endowed with the stem cell-like attributes of self-renewal, multipotency and the ability to undergo asymmetric division. Similar to conventional stem cells, evolutionarily conserved pathways regulating stemness are active in antigen-experienced T cells, especially T SCM cells, T H 17 cells and IL-17-producing CD8 + T cells. As T cells transition through progressive stages of differentiation, they undergo a stepwise loss of stem cell-associated attributes, including proliferative potential, survival fitness and multipotency.
Collectively, these functional changes result in cells that are therapeutically less efficacious upon adoptive transfer. Understanding the epigenetic, genetic and metabolic programmes that regulate T cell self-renewal and persistence provides the ability to pharmacologically or genetically confer stemness to tumour-specific T cells.
Building on recent technologies that have allowed the reprogramming of differentiated somatic cells into iPS cells or cell types of alternative lineages, it is now possible to envision dedifferentiating senescent tumourreactive T cells from a cancer patient to generate antitumour T cells with improved fitness and therapeutic efficacy for adoptive T cell transfer. The application of regenerative medicine technology to T cell therapies for the treatment of cancer patients using iPS-derived or reprogrammed T cells has several advantages. Terminally ill patients with advanced cancer that is refractory to existing therapies have a favourable risk/benefit ratio profile for receiving reprogrammed cells that might have oncogenic potential 182 . Moreover, safety might be ensured by introducing suicide genes in reprogrammed cells to enable the elimination of infused cells if transformation or other adverse events occur 183, 184 . In addition, lymphocytes are motile circulating cells that are capable of autonomously finding their targets, so they do not suffer the 'anatomical' problems that plague regenerative medicine efforts in other organ systems, in which fine interactions between cell types are required for proper functioning 185 . Finally, the routine use of immune ablation before adoptive immunotherapy 150 might avoid immune-mediated rejection of reprogrammed cells 186 . In summary, preserving and regenerating stem cell-like qualities in T cells may finally enable cancer immunotherapists to fight 'fire with fire' with ever increasing effectiveness.
